Literature DB >> 27128367

Intracerebroventricular Infusion of Angiotensin-(1-7) Ameliorates Cognitive Impairment and Memory Dysfunction in a Mouse Model of Alzheimer's Disease.

Ken Uekawa1, Yu Hasegawa1, Satoru Senju2, Naomi Nakagata3, Mingjie Ma1, Takashi Nakagawa1, Nobutaka Koibuchi1, Shokei Kim-Mitsuyama1.   

Abstract

This work was performed to test our hypothesis that angiotensin-(1-7) can ameliorate cognitive impairment and cerebrovascular reactivity in 5XFAD mice, a useful model of Alzheimer's disease. 5XFAD mice received intracerebroventricular infusion of (1) vehicle, (2) angiotensin-(1-7), or (3) angiotensin-(1-7)+A779, a specific Mas receptor antagonist, for 4 weeks. Angiotensin-(1-7), through Mas receptor, significantly ameliorated cognitive impairment in 5XFAD mice. As estimated by acetazolamide-induced increase in cerebral blood flow, angiotensin-(1-7), through Mas receptor, enhanced cerebrovascular reactivity in 5XFAD mice. In conclusion, angiotensin-(1-7)/Mas receptor axis improves cognitive function and cerebrovascular function in a mouse model of Alzheimer's disease.

Entities:  

Keywords:  Acetazolamide; Mas receptor; angiotensin-(1–7); cognitive function; vascular reactivity; water maze test

Mesh:

Substances:

Year:  2016        PMID: 27128367     DOI: 10.3233/JAD-150642

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  13 in total

Review 1.  Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22.

Authors:  Sadashiva S Karnik; Khuraijam Dhanachandra Singh; Kalyan Tirupula; Hamiyet Unal
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

2.  Protective role of ACE2-Ang-(1-7)-Mas in myocardial fibrosis by downregulating KCa3.1 channel via ERK1/2 pathway.

Authors:  Li-Ping Wang; Su-Jing Fan; Shu-Min Li; Xiao-Jun Wang; Jun-Ling Gao; Xiu-Hong Yang
Journal:  Pflugers Arch       Date:  2016-09-03       Impact factor: 3.657

Review 3.  Brain Vasculature and Cognition.

Authors:  Abdelrahman Y Fouda; Susan C Fagan; Adviye Ergul
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

4.  Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies.

Authors:  Jean K Ho; Daniel A Nation
Journal:  Neurosci Biobehav Rev       Date:  2018-05-04       Impact factor: 8.989

Review 5.  Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

Authors:  Geetika Nehra; Bjoern Bauer; Anika M S Hartz
Journal:  Pharmacol Ther       Date:  2022-01-30       Impact factor: 13.400

6.  Detrimental Effects of Centrally Administered Angiotensin II are Enhanced in a Mouse Model of Alzheimer Disease Independently of Blood Pressure.

Authors:  Koki Takane; Yu Hasegawa; Bowen Lin; Nobutaka Koibuchi; Cheng Cao; Takashi Yokoo; Shokei Kim-Mitsuyama
Journal:  J Am Heart Assoc       Date:  2017-04-20       Impact factor: 5.501

7.  ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Charles E Evans; James S Miners; Giulia Piva; Christine L Willis; David M Heard; Emma J Kidd; Mark A Good; Patrick G Kehoe
Journal:  Acta Neuropathol       Date:  2020-01-25       Impact factor: 15.887

Review 8.  Cognitive impact of COVID-19: looking beyond the short term.

Authors:  Scott Miners; Patrick G Kehoe; Seth Love
Journal:  Alzheimers Res Ther       Date:  2020-12-30       Impact factor: 6.982

9.  Blood-Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis.

Authors:  Jean K Ho; Frank Moriarty; Jennifer J Manly; Eric B Larson; Denis A Evans; Kumar B Rajan; Elizabeth M Hudak; Lamiaa Hassan; Enwu Liu; Nobuyuki Sato; Naoyuki Hasebe; Danielle Laurin; Pierre-Hugues Carmichael; Daniel A Nation
Journal:  Hypertension       Date:  2021-06-21       Impact factor: 9.897

Review 10.  Targeting Renin-Angiotensin System Against Alzheimer's Disease.

Authors:  Abadi Kahsu Gebre; Birhanetensay Masresha Altaye; Tesfay Mehari Atey; Kald Beshir Tuem; Derbew Fikadu Berhe
Journal:  Front Pharmacol       Date:  2018-04-30       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.